The Impact of Clinical Trials in the Management of ALL
Sabina Chiaretti, MD PhD
Div. of Hematology, Dept. of Cellular Biotechnologies and Hematology,
"Sapienza" University of Rome,
Via Benevento 6, 00161, Rome, Italy
Acute lymphoblastic leukemia is a rare disease in adulthood. While a great progress has been documented in the pediatric setting over the years, the outcome of adults is still unsatisfactory. The recognition of specific groups, the introduction of targeted therapies in clinical trials as well as the use of pediatric-inspired and MRD (minimal residual disease) regimens is leading to an improvement in the outcomes of such difficult to treat disease. The clinical trials carried out within the GIMEMA network over the last years will be presented during the meeting. Similarly, since immunotherapeutic compounds currently represent a new player in the therapeutic armamentarium, their use in front-line setting will be also discussed.